Sunlenca (lenacapavir)

Many patients pay $0 through manufacturer patient assistance programs. Contact our pharmacists — we handle all the paperwork.

Sunlenca (lenacapavir) is a first-in-class HIV capsid inhibitor for adults with multidrug-resistant HIV-1 who are failing their current regimen. It is administered by subcutaneous injection every 6 months as part of a combination antiretroviral regimen.

Our clinical pharmacists provide specialized support for patients on Sunlenca, including injection coordination, side effect monitoring, and medication therapy management.

• First-in-class capsid inhibitor
• Every-6-month subcutaneous injection
• For treatment-experienced patients
• Full clinical pharmacist support